155158-97-7|DMP 728|2-((5S,11S,14R)-14-ethyl-11-(3-guanidinopropyl)-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-1(1,3)-benzenacyclohexadecaphane-5-yl)acetic acid compound with methanesulfonic acid (11)|-范德生物科技公司

DMP 728

NMR下载 COA and HPLC MSDS下载
names：
2-((5S,11S,14R)-14-ethyl-11-(3-guanidinopropyl)-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-1(1,3)-benzenacyclohexadecaphane-5-yl)acetic acid compound with methanesulfonic acid (11)
CAS号：
155158-97-7
MDL Number：
MF(分子式)： C26H40N8O10S MW(分子量)： 656.71
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	DMP 728
英文别名	DMP 728; DMP-728; DMP728; XL 118; XL-118; XL118;
CAS号	155158-97-7
SMILES	CC[C@@H]1C(N(C)[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(NCc2cc(C(N1)=O)ccc2)=O)=O)=O)=O.CS(=O)(O)=O
Inchi	InChI=1S/C25H36N8O7.CH4O3S/c1-3-16-24(40)33(2)18(8-5-9-28-25(26)27)23(39)30-13-19(34)31-17(11-20(35)36)22(38)29-12-14-6-4-7-15(10-14)21(37)32-16;1-5(2,3)4/h4,6-7,10,16-18H,3,5,8-9,11-13H2,1-2H3,(H,29,38)(H,30,39)(H,31,34)(H,32,37)(H,35,36)(H4,26,27,28);1H3,(H,2,3,4)/t16-,17+,18+;/m1./s1
InchiKey	CSRWGJAILKTYLJ-PWGAQZMISA-N
分子式 Formula	C26H40N8O10S
分子量 Molecular Weight	656.71
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	DMP 728(CAS:155158-97-7):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	DMP 728 is a Glycoprotein IIb-IIIa atagonist.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Shi G, Lloyd TL, Sy SK, Jiao Q, Wernicki A, Mutlib A, Emm TA, Unger SE, Pieniaszek HJ Jr. Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations. J Pharm Biomed Anal. 2003 Apr 1;31(5):937-5[1]PubMed PMID: 12684106.

[2]Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro. J Lab Clin Med. 2000 Mar;135(3):247-55. PubMed PMID: 10711863.

[3] Rebello SS, Huang J, Faul JD, Lucchesi BR. Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists. J Thromb Thrombolysis. 2000 Jan;9(1):23-8. PubMed PMID: 10590185.

[4] Huang J, Rebello SS, Faul JD, Lucchesi BR. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition. Pharmacology. 1999 May;58(5):252-64. PubMed PMID: 10087466.

[5] Boxus T, Touillaux R, Dive G, Marchand-Brynaert J. Synthesis and evaluation of RGD peptidomimetics aimed at surface bioderivatization of polymer substrates. Bioorg Med Chem. 1998 Sep;6(9):1577-95. PubMed PMID: 9801829.

6: Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res. 1998 Jun 15;90(6):247-58. PubMed PMID: 9700855.7: Hantgan RR, Mousa SA. Inhibition of platelet-mediated clot retraction by integrin antagonists. Thromb Res. 1998 Mar 15;89(6):271-9. PubMed PMID: 9669749.8: Mousa SA, Bozarth JM, Edwards S, Carroll T, Barrett J. Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis. Coron Artery Dis. 1998;9(2-3):131-41. PubMed PMID: 9647415.9: Michaelis W, Turlapaty P, Gray J, Fiske WD, Faulkner E, Kornhauser D, Mousa SA. Pharmacodynamics and pharmacokinetics of DMP 728, a platelet GPIIb/IIIa antagonist, in healthy subjects. Clin Pharmacol Ther. 1998 Mar;63(3):384-92. PubMed PMID: 9542482.10: Tsao PW, Forsythe MS, Mousa SA. Dissociation between the anti-aggregatory

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开